Evoke Pharma (EVOK) investor relations material

Executive summary

• Net product sales for Q2 2025 were $3.75–$3.8 million, up 47% year-over-year, driven by expanded pharmacy network and higher refill rates.

• Net loss for Q2 2025 was $1.57–$1.6 million, reflecting increased SG&A expenses.

• Cash and cash equivalents as of June 30, 2025, were $12.1 million, expected to fund operations into Q3 2026, but substantial doubt exists about going concern due to potential early loan repayment.

• Commercialization of Gimoti remains the sole revenue source, with continued investment in marketing and post-marketing clinical trials.

• Real-world safety data for Gimoti presented at DDW 2025, focusing on tardive dyskinesia incidence.

Financial highlights

• Net product sales for the six months ended June 30, 2025, were $6.83 million, up 59% year-over-year.

• Operating loss for Q2 2025 was $1.56 million, with a net loss per share of $0.62.

• SG&A expenses for Q2 2025 increased to $5.1 million from $3.7 million year-over-year, mainly due to higher marketing, profit sharing, and professional fees.

• Cash used in operating activities for the first half of 2025 was $1.56–$1.6 million, a decrease from $3.4 million in the prior year period.

• Weighted-average shares outstanding for Q2 2025 were 2,553,174.

Outlook and guidance

• Full-year 2025 net product sales guidance confirmed at $16 million, representing up to 60% growth over 2024.

• Existing cash and projected sales are expected to fund operations into Q3 2026, but additional financing will be required to continue as a going concern.

• Guidance incorporates assumptions on prescription growth, refill rates, payer reimbursements, and macroeconomic factors.

• Ongoing commercialization activities for Gimoti and a post-marketing PK clinical trial are planned.

• Management anticipates continued operating losses until Gimoti sales exceed expenses.